(Q54383059)

29 May 2018

title

A phase II trial of PTK787/ZK 222584 in recurrent or progressive radiation and surgery refractory meningiomas. (English)

1 reference

29 May 2018

main subject

phase II clinical trial

0 references

vatalanib

1 reference

ChEBI release 2020-05-28

1 reference

ChEBI release 2020-05-28

Jeffrey J Raizer

1

1 reference

29 May 2018

Sean A Grimm

2

1 reference

29 May 2018

Alfred Rademaker

3

1 reference

29 May 2018

James P Chandler

4

1 reference

29 May 2018

Kenji Muro

5

1 reference

29 May 2018

Irene Helenowski

6

1 reference

29 May 2018

Laurie Rice

7

1 reference

29 May 2018

Katie McCarthy

8

1 reference

29 May 2018

Sandra K Johnston

9

1 reference

29 May 2018

Maciej M Mrugala

10

1 reference

29 May 2018

Marc Chamberlain

11

1 reference

29 May 2018

publication date

22 January 2014

1 reference

29 May 2018

Journal of Neuro-Oncology

published in

1 reference

29 May 2018

volume

117

1 reference

29 May 2018

issue

1

1 reference

29 May 2018

page(s)

93-101

1 reference

29 May 2018

Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08).

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1358-9

Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1358-9

Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1358-9

Temozolomide for treatment-resistant recurrent meningioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1358-9

Salvage chemotherapy with CPT-11 for recurrent meningioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1358-9

Atypical and anaplastic meningiomas treated with bevacizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1358-9

Long-term administration of mifepristone (RU486): clinical tolerance during extended treatment of meningioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1358-9

A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a Southwest Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1358-9

Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1358-9

Human meningiomas co-express platelet-derived growth factor (PDGF) and PDGF-receptor genes and their protein products

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1358-9

21 January 2018

Biology of meningiomas

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1358-9

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1358-9

Different distribution of c-myc and MIB-1 positive cells in malignant meningiomas with reference to TGFs, PDGF, and PgR expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1358-9

Epidermal growth factor receptor family (EGFR, ErbB2-4) in gliomas and meningiomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1358-9

Expression and activation of epidermal growth factor receptors in meningiomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1358-9

Mitogenic signal transduction pathways in meningiomas: novel targets for meningioma chemotherapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1358-9

Aberrant signaling pathways in meningiomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1358-9

Expression of fibroblast growth factor receptor-1 in human glioma and meningioma tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1358-9

Imatinib mesylate treatment of recurrent meningiomas in preselected patients: a retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1358-9

Optimal two-stage designs for phase II clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1358-9

Interferon-alpha for recurrent World Health Organization grade 1 intracranial meningiomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1358-9

Hydroxyurea chemotherapy for meningiomas: enlarged cohort with extended follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1358-9

Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1358-9

Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1358-9

Phase II study of subcutaneous octreotide in adults with recurrent or progressive meningioma and meningeal hemangiopericytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1358-9

Fibroblast growth factor receptor-3 expression in meningiomas with stimulation of proliferation by the phosphoinositide 3 kinase-Akt pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1358-9

Angiogenesis in intracranial meningiomas: immunohistochemical and molecular study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1358-9

Vascular endothelial growth factor signals through platelet-derived growth factor receptor β in meningiomas in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1358-9

Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1358-9

Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1358-9

Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-014-1358-9

Lack of efficacy of megestrol acetate in the treatment of unresectable meningioma

21 January 2018

1 reference

12 December 2020

The molecular genetics and tumor pathogenesis of meningiomas and the future directions of meningioma treatments.

1 reference

12 December 2020

Response criteria for phase II studies of supratentorial malignant glioma

1 reference

12 December 2020

PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration

1 reference

12 December 2020

Gene expression of insulin-like growth factor II in human intracranial meningioma

1 reference

12 December 2020

Recurrent meningioma: salvage therapy with long-acting somatostatin analogue

1 reference

12 December 2020

Vascular endothelial growth factor, hepatocyte growth factor/scatter factor, basic fibroblast growth factor, and placenta growth factor in human meningiomas and their relation to angiogenesis and malignancy

1 reference

12 December 2020

Hydroxyurea for recurrent surgery and radiation refractory high-grade meningioma

1 reference

12 December 2020

Hydroxyurea for recurrent surgery and radiation refractory meningioma: a retrospective case series

1 reference

12 December 2020

Angiogenesis as a predictor of recurrence in meningiomas

1 reference

12 December 2020

Autocrine growth stimulation of human meningioma cells by platelet-derived growth factor

1 reference

12 December 2020

Recurrence of meningiomas

1 reference

12 December 2020

Involvement of disregulated c-myc but not c-sis/PDGF in atypical and anaplastic meningiomas

1 reference

12 December 2020

10.1007/S11060-014-1358-9

Identifiers

DOI

1 reference

29 May 2018

1 reference

29 May 2018